To get a sense of who is truly in control of Bristol-Myers Squibb Company (NYSE:BMY), it is important to understand the ...

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

We recently published 8 Stocks That Jim Cramer Recently Talked About. Bristol-Myers Squibb Company (NYSE:BMY) is one of the ...

The companies’ new effort would bypass traditional middlemen to cut the drug’s monthly cost from a list price of around $606 ...

Bristol Myers Squibb Co. closed 26.69% short of its 52-week high of $63.33, which the company achieved on March 11th.

Bristol Myers Squibb Co. closed 25.25% below its 52-week high of $63.33, which the company reached on March 11th.

The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.

The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...

Despite a phase 3 flop, Bristol Myers Squibb—encouraged by “clinically meaningful results” and bruised by three other recent ...

Bristol Myers Squibb & Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating ...

BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while ...

The reduced rate will still be almost 10 times the average monthly out-of-pocket costs paid by commercially insured patients.